Karen Lasch Healthcare News

This is selected healthcare news for Karen Lasch, which is filed under People. There are 7 news items for this page. A press release filter page is also available for Karen Lasch.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/17/2020 Miach Orthopaedics’ BEAR® Implant Granted FDA De Novo Approval for Treatment of ACL Tears
WESTBOROUGH, Mass.- Miach Orthopaedics , Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced that the U.S. Food & Drug Administration has granted the company's De Novo Request for the Bridge-Enhanced¬AE ACL Repair (BEAR¬AE) Implant, resulting in marketing approval ...
Business Wire
12/17/2020 FDA accepts Takeda’s NDA, grants review for budesonide oral suspension
... investigational therapy budesonide oral suspension intended for the treatment of eosinophilic esophagitis. ‚AuEoE is a chronic, immune-mediated, inflammatory disease localized in the esophagus,‚Au Karen Lasch, MD, vice president , g astroenterology, U.S. Medical , told Healio Gastroenterology . ‚AuIf left untreated, inflammation of EoE can worsen and narrow the esophagus over ...
healio.com
5/9/2019 U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
... VISIBLE 1 study provides us with important knowledge on the characterization of the efficacy and safety profile for the investigational subcutaneous formulation of vedolizumab,” said Karen Lasch, M.D., Medical Head, Specialty GI, U.S. Medical Office, Takeda. “Takeda is deeply committed to bringing innovative medicines and treatment modalities to patients living ...
Business Wire
11/9/2017 New Post-Hoc Analysis Evaluating Deep Remission with Entyvio® (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as “Poster of Distinction” at AIBD 2017 Annual Conference
... order to help the GI community determine what goals might be important for patients with the increasing number of treatment options available for IBD," said Karen Lasch , M.D., Medical Head, GI Specialty, U.S. Medical Office, Takeda. "As deep remission becomes an important and realistic treatment goal, Takeda will continue to ...
PR Newswire
11/9/2017 New Post-Hoc Analysis Evaluating Deep Remission with Entyvio® (vedolizumab) in Patients with
... order to help the GI community determine what goals might be important for patients with the increasing number of treatment options available for IBD," said Karen Lasch , M.D., Medical Head, GI Specialty, U.S. Medical Office, Takeda. "As deep remission becomes an important and realistic treatment goal, Takeda will continue to ...
PR Newswire
10/16/2017 New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients
... a biologic." "The symptoms of inflammatory bowel disease (IBD) have a significant impact on the daily lives of millions of people around the world," said Karen Lasch , M.D., Medical Head, GI Specialty, U.S. Medical Office, Takeda. "While patients require lifelong disease management, Takeda's presentation of data evaluating early improvement in ...
PR Newswire
10/16/2017 New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active
... a biologic." "The symptoms of inflammatory bowel disease (IBD) have a significant impact on the daily lives of millions of people around the world," said Karen Lasch , M.D., Medical Head, GI Specialty, U.S. Medical Office, Takeda. "While patients require lifelong disease management, Takeda's presentation of data evaluating early improvement in ...
PR Newswire